Insights into proton pump inhibitor-induced photosensitivity: An observational study in a tertiary photobiology service

J R Coll Physicians Edinb. 2022 Dec;52(4):287-291. doi: 10.1177/14782715221132858. Epub 2022 Oct 25.

Abstract

Background: Proton pump inhibitors (PPIs) are extensively prescribed but may cause photosensitivity and drug-induced lupus erythematosus (DILE), which can be overlooked as the drug may have been taken for years prior to presentation.

Methods: We reviewed the clinical and investigation findings of patients diagnosed with PPI-induced photosensitivity, diagnosed through the Scottish Photobiology Service.

Results: We report 11 patients with median age of onset 61-years and mean duration of PPI ingestion of 5-years [DILE (n = 6), phototoxicity (n = 3) and drug-induced solar urticaria through a lupus mechanism (n = 2)]. Five had Anti-Ro antibodies (three also ANA positive). Predominantly UVA and visible light photosensitivity was observed on phototesting.

Discussion: PPIs are a reversible cause of photosensitivity and DILE. Time to onset from drug initiation to symptoms can be prolonged, so clinicians should have a high index of suspicion in those taking PPIs. Most are diagnosed through clinical assessment and lupus serology, with phototesting indicated if there is diagnostic uncertainty.

Keywords: Ro antibodies; lupus; photosensitivity; phototesting; phototoxicity; proton pump inhibitor.

Publication types

  • Review

MeSH terms

  • Humans
  • Lupus Erythematosus, Cutaneous* / chemically induced
  • Lupus Erythematosus, Cutaneous* / diagnosis
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / drug therapy
  • Middle Aged
  • Observational Studies as Topic
  • Photobiology
  • Photosensitivity Disorders* / chemically induced
  • Photosensitivity Disorders* / diagnosis
  • Proton Pump Inhibitors / adverse effects

Substances

  • Proton Pump Inhibitors